Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary …
T Ito, H Fujita, T Tani, N Ohte - Atherosclerosis, 2015 - Elsevier
Objective Patients undergoing lipid-lowering therapy after percutaneous coronary
intervention (PCI) with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde …
intervention (PCI) with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde …
Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary …
T Ito, H Fujita, T Tani, N Ohte - Atherosclerosis, 2015 - infona.pl
Patients undergoing lipid-lowering therapy after percutaneous coronary intervention (PCI)
with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde-modified low …
with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde-modified low …
[引用][C] Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous …
T Ito, H Fujita, T Tani, N Ohte - Atherosclerosis, 2015 - cir.nii.ac.jp
Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients
with stable angina on lipid-lowering therapy after percutaneous coronary intervention using …
with stable angina on lipid-lowering therapy after percutaneous coronary intervention using …
Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary …
T Ito, H Fujita, T Tani, N Ohte - Atherosclerosis, 2015 - europepmc.org
Objective Patients undergoing lipid-lowering therapy after percutaneous coronary
intervention (PCI) with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde …
intervention (PCI) with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde …
Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary …
T Ito, H Fujita, T Tani, N Ohte - Atherosclerosis, 2015 - pubmed.ncbi.nlm.nih.gov
Objective Patients undergoing lipid-lowering therapy after percutaneous coronary
intervention (PCI) with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde …
intervention (PCI) with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde …
Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary …
T Ito, H Fujita, T Tani, N Ohte - Atherosclerosis, 2015 - atherosclerosis-journal.com
Objective Patients undergoing lipid-lowering therapy after percutaneous coronary
intervention (PCI) with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde …
intervention (PCI) with drug-eluting stent (DES) are subject to residual risk. Malondialdehyde …